Clinical trial
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With…
NCT00095381 · BioCryst Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00095381 |
|---|---|
| Title | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia |
| Official title | A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use |
| Lead sponsor | BioCryst Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, T-Cell |
| Intervention type | Drug |
| Interventions | forodesine hydrochloride (BCX-1777) |
| Enrollment | 20 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 4, 2004 |
| Last update posted | Jan 19, 2012 |
| Countries | Georgia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: